focus -WSS

focus

author：entertainment 2025-09-27 10:04:03 - browse：582

John Thune raises one hand while speaking to the press at the Capitol 2024 — politics coverage from STAT — Sen. John Thune is one of a group of lawmakers that is working on 340B reform legislation. BRENDAN SMIALOWSKI/AFP via Getty Images

WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial disputes in the 340B drug discount program, according to documents obtained by STAT.

The drug discount program, which was designed to support providers that serve low-income patients, has been increasingly contentious as it’s grown in recent years. The draft legislation makes a number of changes to address some of the most controversial points, including its rules over so-called “contract pharmacies” and which subsidiaries can qualify for discounts.

The draft would also require more oversight, and it would give the Health Resources and Services Administration more money to do it with a new user fee program. Providers would pay HRSA up to 0.1% of the savings it receives from the program.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Novo Nordisk testing Wegovy against alcohol

entertainment

WSS

Pediatric cancer treatments threatened by a new FDA policy

30 years of 'Listening to Prozac'

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Diagnostic tests are hitting their mathematical limits

The United States must get value

focus

focus

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

ALS treatment from Biogen, Ionis fails in study

Wildfire smoke exposes gaps in outdoor worker protections

Galapagos to make CAR

Walensky prepares to leave CDC — and Congress — behind

Fetal surgery at risk from Dobbs and new abortion restrictions

How one medical school became remarkably diverse

Ripples from Flovent's discontinuation is killing children with asthma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The EPA's new lead rule: How one expert crunched the numbers

knowledge

The EPA's new lead rule: How one expert crunched the numbers

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Organ aging and disease risk measured by new blood test

HHS suspends federal funding for EcoHealth Alliance

WuXi Biologics execs register to lobby as Congress comes for the company

CDC director unscathed in first congressional testimony

focus

entertainment

explore

focus